Onconova's myelodysplastic syndrome drug enters Phase III trial

05/12/2013 | Pharmaceutical Business Review Online

Onconova Therapeutics has finished enrolling 270 myelodysplastic syndrome patients for a late-stage trial of rigosertib. The trial will be carried out in the U.S. and five countries in the European Union, with overall survival as main endpoint. The firm expects to release data either in the fourth quarter of this year or the first quarter of next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID